|
|
 |
|
Viewing report
|
|
|
|
Commercial Insight: Cardiovascular Market Overview - Raft of Patent Expires Threaten Blockbusters
Datamonitor, Oct 2007, Pages: 262
Introduction
The cardiovascular market is exptected to remain stable with sales only showing negligible growth between 2006 and 2016, below the 3% growth predicted for the SU sold. Generic products will become increasingly important as the majority of products will have lost IP protection, accounting for 30% of cardiovascular sales and 65% of SU sold in 2016.
Scope
- Comprehensive analysis of the cardiovascular market by disease area in each of the seven major markets
- An assessment of trends within the cardiovascular market between 2003 and 2006.
- Intellectual Property risk assessment for Top 10 brands in each market.
- Forecast models for key brands, active agents and pipeline products up to 2016.
Highlights
The cardiovascular market in the seven major markets is a mature market with negligible sales growth between 2006 and 2016. Growth of SU sold in the cardiovascular market is expected to increase by 3%, driven by population growth, leaving an effective cardiovascular sales growth of -3%. Use of generics will increase as key products lose patent protection and healthcare providers push for greater cost containment. Patent expiries during the pivotal 2010-13 window expose $30.9 billion worth of branded drugs to generic competition. Cardiovascular pipeline products are unlikely to make a significant impact on the market with only 16% ($11.9 billion) of 2016 sales generated from the current pipeline. A number of blockbuster products are likely to be launched but the sales are likely to be greatly reduced from the levels seen in 2006.
Reasons to Purchase
- Understand market specific drivers and predict the future potential of key cardiovascular brands
- Quantify the impact of key patent expiries and product launches and gain a valuable insight into the market dynamics
- Consider, assess and react to opportunities and risks influencing the leading cardiovascular brands
Customers who bought this item also bought
Commercial Insight: Cardiovascular and Metabolic Market Overview Diabetes to the Fore as Generics Hit Primary Care Markets
Generics Series: Generics Trends in the Seven Major Markets and Beyond
Cardiovascular Generic Drugs: Prospects and Opportunities to 2012
The Cardiovascular Disorders Market Outlook to 2012
European Cardiovascular Drugs Markets
Cardiovascular Drug Discoveries 2008
The Cardiovascular Market Outlook to 2010
The Cardiovascular Market Outlook to 2013: Competitive Landscape, Global Market Analysis and Pipeline Analysis
The Cardiovascular Market Outlook to 2008
Pricing & Reimbursement - Seven Major Markets Update
Global Cardiovascular Device Markets 2007-2012
The Asian Cardiovascular Market Outlook to 2014: Regional and Therapeutic Analysis, Pipeline Impact and Growth Opportunities
|
|
|
|
